← Leaderboards
Rina Plattner
University Of Kentucky
$6,723,029
Attributed
$8,284,124
Total exposure
8
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $976.3K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,284,124 · 8
By mechanism
R01$6,975,683 · 4
P20$980,412 · 3
P30$328,029 · 1
Top collaborators
- Jill Marie Kolesar4 shared
- Melissa A Wilson4 shared
Most similar at University Of Kentucky
Same institution · by research overlap
- David M Kaetzel$5,001,400
- Avindra Nath$17,882,997
- Daret K St Clair$20,807,410
- Stephen W Scheff$7,594,722
- Kathryn M Thrailkill$1,641,998
Others in their field
Top investigators on “Phosphotransferases”
- David Heimbrook · Leidos Biomedical Research, Inc.$26,594,235
- Gary L. Johnson · National Jewish Health$21,727,284
- Peter Karl Sorger · Massachusetts Institute Of Technology$20,231,592
- Lewis C Cantley · Beth Israel Deaconess Medical Center$19,866,259
- Richard L Huganir · Johns Hopkins University$18,390,405
- Fulton T Crews · University Of North Carolina Chapel Hill$17,915,277
Research focus
PhosphotransferasesPathway InteractionsNeoplasm MetastasisMolecularRna InterferenceCellsBaseBiologicalSignal TransductionBiochemicalCell LinePreventMediatingMalignant NeoplasmsLeukemiaResistanceFda ApprovedMetastatic MelanomaInsightPlayIn VitroMelanomaAbl1 GeneSolid Neoplasm
Grant awards (27)
Combating melanoma resistance by targeting ABL1/2$582,247
R01 · FY2025 · CA · contact PI
Molecular and Cellular Oncology Research Program$53,888
P30 · FY2025 · CA · contact PI
Combating melanoma resistance by targeting ABL1/2$553,135
R01 · FY2024 · CA · contact PI
Molecular and Cellular Oncology Research Program$49,167
P30 · FY2024 · CA · contact PI
Combating melanoma resistance by targeting ABL1/2$571,489
R01 · FY2023 · CA · contact PI
Molecular and Cellular Oncology Research Program$224,974
P30 · FY2023 · CA · contact PI
Combating melanoma resistance by targeting ABL1/2$634,772
R01 · FY2022 · CA · contact PI
Targeting Abl kinases in BRAF-driven melanomas$341,515
R01 · FY2022 · CA · contact PI
Targeting Abl kinases in BRAF-driven melanomas$348,484
R01 · FY2021 · CA · contact PI
Targeting Abl kinases in BRAF-driven melanomas$348,484
R01 · FY2020 · CA · contact PI
Targeting Abl kinases in BRAF-driven melanomas$338,028
R01 · FY2019 · CA · contact PI
Targeting Abl kinases in BRAF-driven melanomas$343,683
R01 · FY2018 · CA · contact PI
A role for c-Abl/Arg in melanoma progression$51,515
R01 · FY2018 · CA · contact PI
A role for c-Abl/Arg in melanoma progression$308,604
R01 · FY2016 · CA · contact PI
A role for c-Abl/Arg in melanoma progression$308,604
R01 · FY2015 · CA · contact PI
A role for c-Abl/Arg in melanoma progression$299,345
R01 · FY2014 · CA · contact PI
A role for c-Abl/Arg in melanoma progression$294,962
R01 · FY2013 · CA · contact PI
A role for c-Abl/Arg in melanoma progression$315,543
R01 · FY2012 · CA · contact PI
Abl Kinases in growth factor signaling, motility, and invasion$259,510
R01 · FY2011 · CA · contact PI
Abl Kinases in growth factor signaling, motility, and invasion$267,536
R01 · FY2010 · CA · contact PI
Abl kinases in growth factor signaling, motility and invasion$268,384
R01 · FY2009 · CA · contact PI
Abl kinases in growth factor signaling, motility and invasion$269,444
R01 · FY2008 · CA · contact PI
Abl kinases in growth factor signaling, motility and invasion$270,399
R01 · FY2007 · CA · contact PI
KY COBRE: PDGF SIGNAL TRANSDUCTION ROLE FOR ABI FAMILY KINASES IN CELL MIGRATIO$252,172
P20 · FY2007 · RR · contact PI
KY COBRE: PDGF SIGNAL TRANSDUCTION ROLE FOR ABI FAMILY KINASES IN CELL MIGRATIO$252,805
P20 · FY2006 · RR · contact PI
KY COBRE: PDGF SIGNAL TRANSDUCTION ROLE FOR ABI FAMILY KINASES IN CELL MIGRATION$238,917
P20 · FY2005 · RR
PDGF SIGNAL TRANSDUCTION--ABI KINASES IN CELL MIGRATION$236,518
P20 · FY2004 · RR